CPACT
recently successfully conducted a feasibility study for GSK Consumer Health on
monitoring of innovation Panadol suspension formulations. This study was part
of a bigger global Process Analytical Technical program at the site where the
goal is to implement a real
time release control testing on multiple products. The
main objective of the program is to reduce the manufacturing cycle time by
improving technical knowledge on bulk manufacture, and to reduce drastically
the release lead-time and inventory so that products reach patients faster.
Paul
Pilloy from GSK highlighted the following points about the benefits of
the study:
- Access
to a variety of spectroscopic techniques is a real asset and to allows to
rapidly select/reject options
- Reactivity
and speed to proceed with laboratory testing.
- Treatment
and interpretation of data, and presentation of results which were well
introduced to GSK via detailed reports